Common names: staph, staph a., or golden staph.

Domain: Bacteria

Class: Bacilli

Family: Staphylococcaceae

Order: Bacillales

Phylum: Bacillota

Cheung GYC, Bae JS, Otto M. Pathogenicity and virulence of Staphylococcus aureus. Virulence. 2021 Dec;12(1):547-569. doi: 10.1080/21505594.2021.1878688. PMID: 33522395; PMCID: PMC7872022.

Lory, S. (2014). The Family Staphylococcaceae . In: Rosenberg, E., DeLong, E.F., Lory, S., Stackebrandt, E., Thompson, F. (eds) The Prokaryotes. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-30120-9_350

M. Stegger, P.E. Akpaka, A. Alabi, S. Breurec, G. Coombs, B. Egyir, A.R. Larsen, F. Laurent, S. Monecke, G. Peters, R. Skov, B. Strommenger, F. Vandenesch, F. Schaumburg, & A. Mellmann, Origin, evolution, and global transmission of community-acquired Staphylococcus aureus ST8, Proc. Natl. Acad. Sci. U.S.A. 114 (49) E10596-E10604, https://doi.org/10.1073/pnas.1702472114 (2017).

Missiakas D and Winstel V (2021) Selective Host Cell Death by Staphylococcus aureus: A Strategy for Bacterial Persistence. Front. Immunol. 11:621733. doi: 10.3389/fimmu.2020.621733

Taylor TA, Unakal CG. Staphylococcus aureus Infection. [Updated 2023 Jul 17]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK441868/

S. aureus infections can spread through contact with an infected wound, skin-to-skin contact with an infected person, and contact with objects used by an infected person.

S. aureus infections have a mortality rate of 10-30% and an estimated incidence of 4.3-38.2 per 100,000 person-years in North America. 

In 2017, there were 50,000 deaths linked to staphylococcal infection in America. 

Its virulence is aided by its ability to produce an array of virulence factors, including toxins, immune evasion factors, and protein factors, that enable host colonisation during infection. Further, S. aureus has a high degree of genetic plasticity, allowing it to acquire new virulence factors, including those that mediate antibiotic resistance, contributing to its evolving capabilities. 

In 1941, penicillin was introduced as a successful treatment for S. aureus infections, but resistance emerged rapidly. The first naturally occurring penicillin-resistant S. aureus was noted in 1942, and by the end of the decade, almost all S. aureus infections were penicillin-resistant.

Meticillin was developed in response and introduced in 1959. Professor Patricia Jevons discovered resistance to meticillin in 1960, and by 1997, meticillin-resistant S. aureus (MRSA) accounted for 50% of hospital S. aureus infections.

MRSA continues to evolve in an arms race against medicine and is endemic in our hospitals and the community. It is often multi-drug resistant, leaving little treatment options and contributing to its high mortality rate.

(Cheung, 2021)

Before the discovery of penicillin, treatment options were limited to topical applications of carbolic acid or other toxic chemicals. Much of the research at the time focused on developing a vaccine.

The discovery of the antibiotic, penicillin, proved effective, but resistance emerged quickly, leading to the antibiotic methicillin. However, S. aureus adapted again, becoming methicillin-resistant (MRSA).

Current treatment options include the glycopeptide antibiotic vancomycin.

Other antibiotics like daptomycin and linezolid, as well as newer agents like telavancin and ceftaroline, are also used to treat S. aureus infections, including MRSA. In the case of severe infection, combination antibiotics may be used to combat population-level mutations.

Infection control measures, such as handwashing and isolation protocols, remain crucial. So does wound care, including drainage of pus and removal of infected tissue.

Active surveillance programs screen for MRSA colonisation, allowing for early detection and implementation of contact precautions. This has also promoted collaboration between healthcare professionals, institutions and departments to track and prevent the spread of resistant strains. Furthermore, hospitals and clinics are implementing antimicrobial stewardship programs to promote judicious use of antibiotics, preventing the development of further resistance. 

Several new technologies are emerging to combat S. aureus and address the threat of antibiotic resistance. Researchers are investigating the use of sugar carriers to transport antibiotics into bacteria, potentially enhancing their effectiveness. Alternatively, other mechanisms for killing the S. aureus include bacteriophage therapy (viruses that infect and kill bacteria). This is explored alongside novel vaccines that can protect against both colonisation and invasive S. aureus infections.

Alongside the development of treatment options, prevention remains a primary objective, so new diagnostic tools, such as micropore technology combined with machine learning, are being developed to improve the accuracy and speed of S. aureus identification. Advanced photohydrolysis technology is also being used to reduce contamination of surfaces and air in healthcare settings.

The appearance of penicillin-resistant strains prompted early hospital infection control policies, but there was no governmental involvement.

MRSA Emergence and Public Health Policy (1960s onward).

As MRSA spread in hospitals globally, governments and hospital leadership began developing stricter infection control practices, including institutionalising hand hygiene protocols, sterilisation guidelines, and patient isolation procedures.

In 1980, the CDC (U.S.) response included MRSA surveillance and prevention in their National Nosocomial Infections Surveillance System (NNIS), while the

the UK’s NHS implemented mandatory MRSA screening for surgical patients in 2000 and published annual hospital infection rates.

Current-Day Handling

Governmental bodies like the CDC, ECDC (European Centre for Disease Prevention and Control), and WHO track MRSA infections through public health surveillance programs.

Governments now promote judicious use of antibiotics in both human and veterinary medicine to prevent resistance. These are called Antibiotic Stewardship Programs.

In hospitals, there is mandatory screening of high-risk patients, use of personal protective equipment, and strict use of environmental cleaning and disinfectant. Further, there is a much greater public awareness through campaigns on hygiene and resistance.

Many countries fund research into new antibiotics, vaccines, and alternative therapies like bacteriophages due to the rise of multidrug-resistant strains.

Finally, there is a global action plan
headed by WHO, initiated in 2015, directly addresses S. aureus and other resistant bacteria, urging member states to improve awareness and surveillance, reduce the incidence of infection, optimise antimicrobial use and invest in research.

Another key innovation has been the development of rapid diagnostic tools to detect S. aureus and differentiate between MRSA strains.

Infection control within healthcare settings has also seen technological and procedural innovation. One example is using ultraviolet (UV) light and hydrogen peroxide vapour systems to decontaminate hospital rooms and equipment.

From a research and pharmaceutical standpoint, efforts have to extend beyond traditional antibiotics in case they fail. Scientists are exploring bacteriophage therapy, which uses viruses that specifically target and kill bacteria like S. aureus, including resistant strains. Moreover, researchers have been investigating anti-virulence therapies.

Another area where leadership failed to regulate was the overuse and unregulated distribution of antibiotics in healthcare and agriculture. For many years, antibiotics were prescribed too liberally, often for viral infections where they were ineffective, contributing to environmental reservoirs of resistant bacteria.

Additionally, there were failings in public health communication. For a long time, MRSA and S. aureus were perceived as primarily hospital-related issues, which left the public underinformed about the risks of community-acquired infections. As MRSA began to emerge in schools, athletic facilities, and other community settings in the early 2000s, the lack of public awareness led to fear, stigma, and misinformation.